Amivantamab for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, you must not have received any systemic therapy, like chemotherapy or immunotherapy, within 21 days before joining the study, and you cannot receive any other cancer treatments while participating.
Is amivantamab safe for humans?
How is the drug Amivantamab unique for treating non-small cell lung cancer?
What data supports the effectiveness of the drug Amivantamab for treating non-small cell lung cancer?
Amivantamab has been shown to be effective for patients with advanced non-small cell lung cancer (NSCLC) that have a specific mutation called EGFR Exon 20 insertion, especially after other treatments like platinum-based chemotherapy have failed. It has been approved for use in the USA and has demonstrated antitumor activity in combination with chemotherapy.12346
Who Is on the Research Team?
Shirish Gadgeel
Principal Investigator
SWOG Cancer Research Network
Are You a Good Fit for This Trial?
This trial is for adults with advanced non-small cell lung cancer that has extra copies of the MET gene. They must have measurable disease, no other actionable cancer mutations, and should have tried at least one systemic treatment before. Participants need a recent CT or MRI scan and stable brain metastases if present.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive amivantamab subcutaneously on days 1, 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Amivantamab-vmjw
Amivantamab-vmjw is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
SWOG Cancer Research Network
Lead Sponsor
National Cancer Institute (NCI)
Collaborator